Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Clin Dermatol ; 39(2): 233-239, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34272016

RESUMO

Cutaneous adverse drug reactions produce a significant clinical, financial, and psychological burden on our healthcare industry. The importance of considering a drug reaction in the cause of any dermatitis is underscored by the diversity of clinical manifestations and the prolific rate of drug discovery and approval. We present an update on the variety of drug reactions encountered in the inpatient and outpatient setting. Immunomodulatory drugs used in oncology will be reviewed separately as their clinical manifestations cross many reaction patters and morphologies.


Assuntos
Toxidermias , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Exantema , Toxidermias/etiologia , Humanos , Pele
3.
Dermatol Online J ; 24(1)2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-29469760

RESUMO

INTRODUCTION: Cyclosporine therapy for Stevens-Johnson syndrome-toxic epidermal necrolysis (SJSTEN) was first reported in the literature by Renfro et al. in 1989. Herein we report an additional 4 cases of SJS-TEN treated with cyclosporine. METHODS: Case information was collected retroactively at the University of Louisville Hospital in Louisville, KY. All cases had a diagnosis of SJS or TEN by a dermatologist. All patients were ≥18 years of age and treated with cyclosporine during their admission. RESULTS: Three of four patients re-epithelialized within an average of 3.67 days of starting 3-4 mg/kg/day of cyclosporine. One patient passed away, likely due to advanced endometrial cancer. DISCUSSION: We provide a review of the literature on cyclosporine use for SJS/TEN, including various outcome measures - stabilization (cessation of new lesions), time to re-epithelialization, mortality rate, and hospital length of stay and, where available, comparison to other systemic agents. CONCLUSION: The outcomes appear to be consistent with rapid re-epithelialization and low mortality as seen in many previous reports. Treating SJS-TEN with systemic agents including cyclosporine will remaincontroversial because the vast majority of data comes from case reports, case series, or small open prospective trials.


Assuntos
Inibidores de Calcineurina/uso terapêutico , Ciclosporina/uso terapêutico , Síndrome de Stevens-Johnson/tratamento farmacológico , Adulto , Idoso , Anti-Inflamatórios/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
4.
Lasers Surg Med ; 48(9): 837-843, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27426441

RESUMO

BACKGROUND AND OBJECTIVE: Ablative laser resurfacing is a common treatment for post-surgical scars. Fractional ablative laser resurfacing has been an emerging treatment option that is replacing fully ablative lasers in many applications. Data comparing fractionated and fully ablative lasers in treating post-operative scars are lacking. STUDY DESIGN: Twenty patients were enrolled in a split scar study following excisions from dermatologic surgery. Wounds had to be older than 8 weeks but less than 1 year. The scars were randomly divided into two halves. One half of the scar was treated with fully ablative erbium-doped yttrium aluminum garnet (Er:YAG) and the other was treated with fractionated Er:YAG. The scars were treated at monthly intervals for 3 months, then followed up at months 1 and 2 after the last treatment. POSAS was used to evaluate the scars by a panel of dermatologists blinded to the lasers in conjunction with the patients, who were also blinded. RESULTS: Physicians and patients both observed a superior outcome of 32.5% (P = 0.019) and 58.1% (P = 0.001), respectively, using the POSAS. There was no trend in difference in pain reported by the patient between the two lasers. Patients overwhelmingly preferred the fractionated Er:YAG laser (94%) to the fully ablative laser when asked at the end of the study. CONCLUSIONS: Although this study is limited by a short follow-up period, it shows a statistically significant superior outcome in fractionated Er:YAG over fully ablative Er:YAG for scar revision. It also adds quantitative values to the assessment of scar appearance when treated with fractionated lasers compared to fully ablative lasers. It was also found that the fractionated Er:YAG had increased patient satisfaction, but there was no difference in reported pain scores. These data are useful when counseling patients undergoing laser surgery. Lasers Surg. Med. 48:837-843, 2016. © 2016 Wiley Periodicals, Inc.


Assuntos
Cicatriz/cirurgia , Lasers de Estado Sólido/uso terapêutico , Adulto , Idoso , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Estudos Prospectivos , Resultado do Tratamento
5.
J Cutan Pathol ; 40(6): 532-7, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23531053

RESUMO

BACKGROUND: Tumor of the follicular infundibulum (TFI) is an uncommon benign adnexal tumor that usually presents as a solitary keratotic papule in the head and neck area. Infrequently, it may present as multiple lesions or in association with other conditions. Although it was initially described in 1961, the pathogenesis of this lesion is still controversial. METHODS: The clinical and histologic features of 168 cases of TFI were reviewed. Random cases were stained with elastic Van Gieson, cytokeratin (CK)20 and Ber-EP4. Clinical data and clinical images were collected. RESULTS: The median age at presentation was 66 years with a slight female predominance. As subset of patients (7.7%) had multiple TFI, some of which presented with hypopigmented lesions of the head and neck area. TFI has a unique staining pattern; all cases tested showed a brush-like network of elastin fibers, no cases stained for Ber-EP4 and 91.7% of cases show single cell positivity to CK20. This is in contrast to basal cell carcinoma used for comparison purposes. CONCLUSION: TFI is a distinct neoplastic entity with a unique staining pattern and variable clinical presentation. One should be aware of the potential clinical presentation of multiple TFI as hypopigmented lesions especially in the head and neck area.


Assuntos
Biomarcadores Tumorais/metabolismo , Neoplasias de Cabeça e Pescoço , Queratina-20/metabolismo , Proteínas de Neoplasias/metabolismo , Neoplasias Primárias Múltiplas , Neoplasias Cutâneas , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Neoplasias de Cabeça e Pescoço/metabolismo , Neoplasias de Cabeça e Pescoço/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Primárias Múltiplas/metabolismo , Neoplasias Primárias Múltiplas/patologia , Neoplasias Cutâneas/metabolismo , Neoplasias Cutâneas/patologia
6.
Arch Dermatol ; 142(10): 1312-4, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17043186

RESUMO

BACKGROUND: African tick bite fever is a rickettsial illness that has recently emerged as a significant disease among international travelers. The vector is the Amblyomma tick, which is endemic to sub-Saharan Africa and parts of the eastern Caribbean. OBSERVATIONS: We describe a middle-aged woman who returned from a mission trip to Zimbabwe with an influenzalike illness and inoculation eschar; she also had a history of travel to a game farm. Biopsy revealed a histopathologic pattern consistent with an infectious pathogenesis. Immunohistochemical staining confirmed the presence of rickettsial organisms. In light of the patient's history, the clinical constellation of signs and symptoms, and the results of ancillary laboratory testing, a diagnosis of African tick bite fever was made. The patient was treated with doxycycline hydrochloride and had an uncomplicated course. CONCLUSIONS: This report further highlights the epidemiological and clinical features of African tick bite fever. With the increase in international travel, it is important to recognize the illness in those who have been to endemic countries and to counsel patients regarding preventive measures for planned travel.


Assuntos
Febre/etiologia , Mordeduras e Picadas de Insetos/diagnóstico , Infecções por Rickettsia/diagnóstico , Carrapatos , Viagem , Animais , Antibacterianos/uso terapêutico , Vetores Aracnídeos , Diagnóstico Diferencial , Doxiciclina/uso terapêutico , Feminino , Humanos , Mordeduras e Picadas de Insetos/complicações , Mordeduras e Picadas de Insetos/patologia , Pessoa de Meia-Idade , Infecções por Rickettsia/complicações , Infecções por Rickettsia/tratamento farmacológico , Infecções por Rickettsia/patologia , Estados Unidos , Zimbábue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...